Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.

Berger J, Pujol A, Aubourg P, Forss-Petter S.

Brain Pathol. 2010 Jul;20(4):845-56. doi: 10.1111/j.1750-3639.2010.00393.x. Review.

2.

Adrenomyeloneuropathy as a cause of primary adrenal insufficiency and spastic paraparesis.

Spurek M, Taylor-Gjevre R, Van Uum S, Khandwala HM.

CMAJ. 2004 Oct 26;171(9):1073-7. Review.

3.

Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B Jr, Wanders RJ, Barth PG.

J Neurol Neurosurg Psychiatry. 1999 Sep;67(3):290-9.

4.

A mouse model for X-linked adrenoleukodystrophy.

Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW, Smith KD.

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9366-71.

5.

X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

van Geel BM, Assies J, Wanders RJ, Barth PG.

J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):4-14. Review.

6.

Adrenoleucodystrophy.

Green SH.

Arch Dis Child. 1991 Jul;66(7):830-2. No abstract available.

Supplemental Content

Support Center